Sage Journals: Discover world-class research

Abstract

Purpose

The present study aimed to compare the dose distributions between conventional three-catheter intracavitary (IC) brachytherapy and combined intracavitary–interstitial (IC/IS) brachytherapy in the management of locally advanced cervical cancer (LACC).

Materials and Methods

A retrospective dosimetric analysis was performed using data from 78 patients with cervical cancer who underwent high-dose-rate (HDR) brachytherapy. To evaluate the dosimetric advantages of IC/IS brachytherapy, patients were stratified into two groups: those treated with IC brachytherapy and those treated with IC/IS brachytherapy. Dosimetric parameters between the two groups were compared.

Results

In the IC/IS brachytherapy group, V150 values for the high-risk clinical target volume (HR-CTV) were significantly higher than those in the IC group (p < 0.001). Subsequent comparison of organ-at-risk (OAR) dosimetric parameters revealed that D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc values for the bladder and sigmoid colon were significantly lower in the IC/IS group than in the IC group (all p < 0.05).

Conclusions

Compared with conventional IC brachytherapy, combined IC/IS brachytherapy provides superior HR-CTV coverage with higher doses while simultaneously reducing radiation exposure to the bladder and sigmoid colon, provided that the D90 dose constraint for the HR-CTV is met.

Graphical Abstract

Keywords

cervix carcinoma brachytherapy intracavitary brachytherapy interstitial brachytherapy dose distribution

1. Introduction

In the radiotherapy of locally advanced cervical cancer (LACC), pelvic external beam radiotherapy (EBRT) is typically administered as the initial treatment modality. However, due to the anatomical location of the cervix, the prescribed dose of pelvic EBRT is limited by adjacent organs at risk (OARs), such as the bladder and colorectum. Notably, pelvic organs—particularly the colorectum—exhibit poor tolerance to ionizing radiation, necessitating the delivery of a supplemental boost via brachytherapy. As a critical component of definitive radiotherapy for cervical cancer, brachytherapy plays an indispensable role; consequently, optimizing local tumor control while minimizing radiation-induced toxicity to surrounding normal tissues has become a central objective in the advancement of radiotherapy technologies.

Brachytherapy has evolved from two-dimensional (2D), point-based dosimetry to three-dimensional (3D), volume-based planning. In particular, image-guided brachytherapy (IGBT) provides a reliable foundation for accurately determining both the therapeutic dose delivered to the tumor and the constrained doses to OARs.¹ The proper placement of brachytherapy applicators is essential for achieving tumor control while maintaining acceptable rates of complications. In patients with large tumor volumes, irregular tumor morphology, or parametrial involvement, conventional intracavitary (IC) brachytherapy often results in incomplete coverage of the target volume and suboptimal dose distribution, thereby compromising therapeutic efficacy. Although interstitial (IS) brachytherapy enables conformal implantation tailored to the shape of the target volume, it may fail to deliver an adequate therapeutic dose to the central region of cervical tumors when used in isolation.² Combined intracavitary–interstitial (IC/IS) brachytherapy offers a complementary approach: it ensures sufficient dose delivery to the central tumor region while achieving comprehensive coverage of the high-risk clinical target volume (HR-CTV). The IC/IS implantation technique involves initial placement of a uterine tandem, followed by the insertion of multiple interstitial needles into the tumor bed to optimize dose conformity and target coverage. Importantly, IC/IS brachytherapy effectively overcomes the limitations of standalone IC brachytherapy and has emerged as a key technique in modern image-guided brachytherapy for cervical cancer.

Although IC/IS brachytherapy has been increasingly adopted in the management of LACC, relatively few studies have comprehensively characterized its dosimetric properties. In the present study, we compared the dosimetric advantages of IC/IS brachytherapy with those of conventional IC brachytherapy, focusing on two primary endpoints: (1) improvement in target volume dose distribution, and (2) reduction in radiation doses to OARs—including the bladder, rectum, and sigmoid colon.

2. Methods and Materials

2.1. Patient Cohort

A total of 78 patients with cervical cancer were retrospectively enrolled from our institution. Specifically, data from patients diagnosed with cervical cancer who underwent high-dose-rate (HDR) brachytherapy between June 2019 and May 2021 were analyzed. Eligible patients were staged according to the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system, with disease stages ranging from IIB to IVA. All patients were scheduled to receive EBRT to a total dose of 45–50.4 Gy. Patients receiving concurrent chemotherapy were treated with cisplatin-based regimens. For those who discontinued chemotherapy due to treatment-related toxicity, the reasons for discontinuation and the number of administered cycles were documented; chemotherapy completion status was included as a covariate in subsequent analyses. Indications for combined IC/IS brachytherapy included eccentric or bulky cervical tumors with inadequate target volume coverage achievable by IC brachytherapy alone, as well as tumors with parametrial or paravaginal involvement. All enrolled patients received intensity-modulated radiation therapy (IMRT) in combination with HDR brachytherapy. Brachytherapy was delivered using a remote afterloading microSelectron HDR Version 3.0 unit (Elekta AB, Stockholm, Sweden) with an iridium-192 (¹⁹²Ir) source. Written informed consent was obtained from all participants, and all study procedures were conducted in accordance with the Declaration of Helsinki and applicable local regulatory requirements.

2.2. Operating Procedure

The radiotherapy procedure followed a standardized protocol. Prior to each brachytherapy session, routine preparatory interventions were performed before applicator implantation, including administration of a cleansing enema, oral intake of contrast agent, placement of an indwelling urinary catheter, and bladder emptying.

Patients in the IC/IS group underwent implantation with a uterine tandem and interstitial needles, whereas those in the IC group received a uterine tandem combined with ovoid intracavitary applicators. The treatment volume and the number of interstitial needles to be implanted were determined based on findings from clinical gynecological examination and complementary imaging studies (e.g., MRI and CT). Interstitial needles were inserted into the cervix, vagina, and parametrial tumor regions to a depth of 1–3 cm, with 4–6 needles typically used and inter-needle spacing maintained at 0.8–1.5 cm. Vaginal packing with gauze was then performed for applicator stabilization, and the depth and orientation of the interstitial needles were adjusted under CT guidance to avoid perforation of the rectum or bladder. Finally, the patient’s bladder was filled with 150 mL of normal saline, followed by acquisition of a CT scan with a slice thickness of 3 mm.

2.3. Contouring

Target volume and OAR delineation were performed in accordance with the consensus guidelines established by the European Society for Radiotherapy and Oncology.^3,4 Contoured structures included the HR-CTV, rectum, bladder, and sigmoid colon. Specifically, the bladder was contoured from the superior bladder fornix to its junction with the urethra. The rectum was contoured from 1 cm above the anal verge to the rectosigmoid junction. The sigmoid colon was delineated along its anatomical course, extending from the rectosigmoid junction to the left iliac fossa (or anterior pelvic region, as appropriate).

All patients received an individualized lymph node irradiation strategy based on FIGO staging and imaging findings (PET/CT or MRI). In patients with suspected or confirmed para-aortic lymph node metastases, the radiation field was extended to include the para-aortic region in addition to standard EBRT. For lymph nodes that were pathologically or radiologically confirmed as positive—defined by a short-axis diameter ≥1 cm and a markedly elevated maximum standardized uptake value (SUVmax) on PET/CT—a simultaneous integrated boost (SIB) or sequential boost was delivered after completion of EBRT, to a total boost dose of 60–63 Gy. Notably, the boost field excluded the uterine body and the upper vaginal segment.

2.4. Treatment Planning

The treatment planning objective was that 90% of the HR-CTV receive 100% of the prescribed dose (6 Gy per fraction), i.e., D90 ≥ 6 Gy. Dose constraints for the bladder, rectum, and sigmoid colon were applied in accordance with the recommendations of the EMBRACE II study group.⁵ All treatment plans were generated using Oncentra Brachytherapy Treatment Planning Software, version 4.1 (Nucletron, Elekta, The Netherlands). Dosimetric parameters were compared between the IC and IC/IS brachytherapy groups. Specifically, to evaluate differences in radiation exposure to OARs, the mean doses corresponding to the following volumetric dose metrics were calculated for the bladder, rectum, and sigmoid colon: D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc.

2.5. Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows, version 26.0 (IBM Corp., Armonk, NY, USA). The normality of data distribution was first assessed. Descriptive statistics for OAR dosimetric parameters are presented as mean ± standard deviation (SD). Between-group differences in dosimetric parameters were evaluated using the independent-samples t-test, with a two-tailed p-value < 0.05 considered statistically significant.

3. Result

As part of definitive treatment for the 78 patients with LACC, a total of 325 brachytherapy implantations were performed (Table 1). No statistically significant differences were observed between the IC and combined IC/IS brachytherapy groups with respect to baseline characteristics, including age, FIGO stage, receipt of concurrent chemotherapy, mean HR-CTV volume, and total EBRT dose (all p > 0.05). Dosimetric comparisons between the two groups were conducted using the independent-samples t-test, and the results are summarized in Tables 2 and 3.

Table 1.

Patient Characteristics

Characteristics	IC group (n = 36)	IC/IS group (n = 42)	p-value
Age(years, mean ± SD)	61.08 ± 11.27	59.57 ± 9.83	0.529
Stage(FIGO 2018)
IIB	10	16
IIIA	6	4
IIIB	7	9	0.501
IIIC	11	8
IVA	2	5
CCRT
Yes	32	40	0.294
No	4	2
Mean volume of HR-CTV(cc)	62.82 ± 17.91	60.05 ± 16.58	0.196
EBRT dose/fraction
45 Gy/25 f	5	11
46 Gy/25 f	12	10
47.5 Gy/25 f	8	7	0.660
48 Gy/25 f	8	10
50.4 Gy/28 f	3	4

HR-CTV = high risk clinical target volume; IC = intracavitary; IS = interstitial; CCRT = concurrent chemoradiotherapy; SD = standard deviation; EBRT = external beam radiation therapy.

Table 2.

Comparison of HR-CTV Parameters of the IC Group and IC/IS Groups

HR-CTV	IC group (cGy)	IC/IS group (cGy)	t-value	Mean difference	p-value
HR-CTV	Mean ± SD	Mean ± SD	t-value	Mean difference	p-value
D90	632.87 ± 20.45	633.86 ± 19.83	-0.435	-0.984	0.664
D100	381.38 ± 56.43	387.99 ± 49.92	-1.114	-6.612	0.266

HR-CTV = high risk clinical target volume; IC = intracavitary; IS = interstitial; SD = standard deviation.

Table 3.

Comparison of HR-CTV Parameters of the IC Group and IC/IS Groups

HR-CTV	IC group (%)	IC/IS group (%)	t-value	Mean difference	p-value
HR-CTV	Mean ± SD	Mean ± SD	t-value	Mean difference	p-value
V150	52.972 ± 11.15	57.624 ± 4.81	-4.970	-4.652	0.000
V200	33.720 ± 8.60	33.683 ± 4.77	0.050	0.037	0.096

HR-CTV = high risk clinical target volume; IC = intracavitary; IS = interstitial; SD = standard deviation.

With regard to HR-CTV dosimetric parameters, no statistically significant differences were found in D₉₀ or D₁₀₀ between the IC and IC/IS groups (both p > 0.05). In contrast, HR-CTV V₁₅₀ was significantly higher in the IC/IS group than in the IC group (p < 0.001), increasing from 52.97% to 57.62%. No significant difference was observed in HR-CTV V₂₀₀ between the two groups. The median and interquartile range (IQR) of HR-CTV V₁₅₀ and V₂₀₀ are presented in box plots (Figures 1 and 2).

Figure 1.

Box plot showing the D₉₀ and D₁₀₀ dose–volume parameters for the HR-CTV in the IC and IC/IS brachytherapy groups.

Figure 2.

Box plot showing the V₁₅₀ and V₂₀₀ of the HR-CTV in the IC and IC/IS brachytherapy groups.

Comparisons of OAR dosimetric parameters yielded the following results:

3.2. Bladder

In the IC group, the mean doses to 0.1 cc, 1 cc, 2 cc, 5 cc, and 10 cc of bladder volume (D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc) were 616.31 ± 108.49 cGy, 521.88 ± 86.14 cGy, 482.15 ± 80.60 cGy, 420.17 ± 74.71 cGy, and 362.55 ± 69.90 cGy, respectively. Corresponding values in the IC/IS group were 578.23 ± 82.94 cGy, 498.23 ± 58.25 cGy, 463.60 ± 54.64 cGy, 404.21 ± 52.48 cGy, and 348.05 ± 54.02 cGy, respectively. As shown in Table 4, all bladder dosimetric parameters were significantly lower in the IC/IS group (all p < 0.05). The median and IQR for these parameters are displayed in Figure 3.

Table 4.

Dose to 0.1 cc, 1 cc, 2 cc, 5 cc and 10 cc Volume of the Bladder

Bladder	IC group (cGy)	IC/IS group (cGy)	t-value	Mean difference	p-value
Bladder	Mean ± SD	Mean ± SD	t-value	Mean difference	p-value
D0.1cc	616.31 ± 108.49	578.23 ± 82.94	3.676	38.084	0.000
D1cc	521.88 ± 86.14	498.23 ± 58.25	2.987	23.654	0.003
D2cc	482.15 ± 80.60	463.60 ± 54.64	2.502	18.555	0.013
D5cc	420.17 ± 74.71	404.21 ± 52.48	2.297	15.955	0.022
D10cc	362.55 ± 69.90	348.05 ± 54.02	2.164	14.499	0.031

IC = intracavitary; IS = interstitial; SD = standard deviation.

Figure 3.

Box plot showing D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc for the bladder in the IC and IC/IS brachytherapy groups.

3.3. Rectum

In the IC group, mean rectal D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc values were 562.90 ± 165.33 cGy, 448.53 ± 126.27 cGy, 394.78 ± 112.85 cGy, 311.24 ± 99.36 cGy, and 228.10 ± 91.51 cGy, respectively. In the IC/IS group, corresponding values were 534.26 ± 119.43 cGy, 434.51 ± 95.14 cGy, 386.53 ± 84.57 cGy, 310.10 ± 71.72 cGy, and 239.05 ± 61.39 cGy, respectively. As shown in Table 5, no statistically significant differences were observed for any rectal dosimetric parameter between the two groups (all p > 0.05). The median and IQR are presented in Figure 4.

Table 5.

Dose to 0.1 cc, 1 cc, 2 cc, 5 cc and 10 cc Volume of the Rectum

Rectum	IC group (cGy)	IC/IS group (cGy)	t-value	Mean difference	p-value
Rectum	Mean ± SD	Mean ± SD	t-value	Mean difference	p-value
D0.1cc	562.90 ± 165.33	534.26 ± 119.43	1.918	28.635	0.056
D1cc	448.53 ± 126.27	434.51 ± 95.14	1.169	14.025	0.243
D2cc	394.78 ± 112.85	386.53 ± 84.57	0.770	8.242	0.442
D5cc	311.24 ± 99.36	310.10 ± 71.72	0.122	1.137	0.093
D10cc	228.10 ± 91.51	239.05 ± 61.39	-1.304	-10.949	0.193

IC = intracavitary; IS = interstitial; SD = standard deviation.

Figure 4.

Box plot showing D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc for the rectum in the IC and IC/IS brachytherapy groups.

3.4. Sigmoid Colon

In the IC group, mean sigmoid colon D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc values were 472.22 ± 126.75 cGy, 389.58 ± 108.18 cGy, 354.35 ± 100.51 cGy, 302.24 ± 91.71 cGy, and 252.39 ± 79.73 cGy, respectively. In the IC/IS group, corresponding values were 430.13 ± 123.71 cGy, 343.02 ± 101.32 cGy, 307.66 ± 91.77 cGy, 253.19 ± 78.72 cGy, and 204.05 ± 66.20 cGy, respectively. As shown in Table 6, all sigmoid colon dosimetric parameters were significantly lower in the IC/IS group (all p < 0.05). The median and IQR are displayed in Figure 5.

Table 6.

Dose to 0.1 cc, 1 cc, 2 cc, 5cc and 10 cc Volume of the Sigmoid

Sigmoid	IC group (cGy)	IC/IS group (cGy)	t-value	Mean difference	p-value
Sigmoid	Mean ± SD	Mean ± SD	t-value	Mean difference	p-value
D0.1cc	472.22 ± 126.75	430.13 ± 123.71	3.165	42.087	0.002
D1cc	389.58 ± 108.18	343.02 ± 101.32	4.191	46.566	0.000
D2cc	354.35 ± 100.51	307.66 ± 91.77	4.580	46.686	0.000
D5cc	302.24 ± 91.71	253.19 ± 78.72	5.430	49.048	0.000
D10cc	252.39 ± 79.73	204.05 ± 66.20	6.249	48.341	0.000

IC = intracavitary; IS = interstitial; SD = standard deviation.

Figure 5.

Box plot showing D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc for the sigmoid in the IC and IC/IS brachytherapy groups.

4. Discussion

Brachytherapy plays a pivotal role in the management of cervical cancer across stages I–IV and serves as an essential component of definitive treatment for LACC. While IC brachytherapy yields favorable outcomes in early-stage disease, its efficacy is suboptimal in LACC. This limitation stems from the inherent characteristics of LACC tumors—including large volume, eccentric location, irregular shape, and a high propensity for parametrial invasion—which render standalone IC brachytherapy incapable of achieving optimal target dose coverage and adequate OAR sparing. As early as 1978, transperineal template-based interstitial applicator implantation was first reported, a technique that improved dose distribution uniformity and laid the foundation for modern IS brachytherapy.⁶ In 2001, the feasibility of combined IC/IS brachytherapy for LACC was first documented and validated.⁷ Subsequent studies have demonstrated that CT-guided 3D brachytherapy delivers higher doses to the central tumor region, with reduced sensitivity to variations in bladder and rectal filling; furthermore, treatment position and respiratory motion do not significantly affect pelvic dose distribution.⁸ The present study retrospectively compares dose distributions between CT-guided IC/IS combined brachytherapy and conventional three-catheter IC brachytherapy in patients with cervical cancer. Theoretically, the IC/IS approach enables superior target volume coverage while minimizing radiation exposure to OARs.

The present study identified differences in target volume dose distribution between the two brachytherapy techniques. Consistent with previous findings,⁹ combined IC/IS brachytherapy offers dosimetric advantages over standalone IC brachytherapy in the treatment of LACC. Prior studies have reported that 100% of patients treated with IC/IS brachytherapy achieved a HR-CTV D₉₀ of at least 85 Gy, compared with only 50% of those receiving IC brachytherapy alone. Notably, HR-CTV V₁₅₀ values were significantly higher in the IC/IS group than in the IC group. These results indicate that IC/IS implantation in LACC enables local dose optimization, facilitating both dose escalation within the central tumor region and expansion of the high-dose volume—findings consistent with prior literature.^9,10 This effect may be attributed to the additional radiation sources introduced via IS implantation needles. When combined with IC applicators, these needles produce dose superposition near the implantation sites, leading to a marked increase in local V₁₅₀. In tumors with pronounced lateral extension or parametrial infiltration, IS needles are essential to ensure adequate target coverage; this often necessitates elevation of the peripheral dose, which indirectly increases the overall high-dose volume.

Similarly, the present study demonstrated that dosimetric parameters for the bladder and sigmoid colon—including D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc—were significantly more favorable in the IC/IS brachytherapy group than in the IC group. These findings confirm that IC/IS brachytherapy enables more conformal dose optimization, allowing precise target irradiation while reducing radiation exposure to OARs, thereby demonstrating superiority over conventional IC brachytherapy in this regard. Notably, however, IC/IS brachytherapy did not significantly reduce rectal doses. Potential explanations for this observation include the following: first, the trajectory of IS implantation needles is anatomically constrained by structures such as the pelvic sidewall and ischial spine, limiting the ability to optimally spare the rectum; second, in patients with pelvic stenosis, the restricted operative space increases the technical difficulty of IS needle placement and may compromise dosimetric outcomes. Importantly, IC/IS brachytherapy facilitates dose escalation to the target volume, enabling attainment of clinically required dose levels without increasing radiation exposure to OARs, owing to the precise positioning of the applicator system.

Despite the widely recognized dosimetric advantages of combined IC/IS brachytherapy over conventional IC brachytherapy, its adoption in routine clinical practice remains limited. The primary barriers include its relatively invasive nature, a higher risk of procedural complications, and a paucity of randomized controlled trials (RCTs) evaluating optimal implantation techniques and dose fractionation regimens.¹¹ Currently, brachytherapy dose fractionation for cervical cancer remains heterogeneous, with no universally standardized protocol; the field is still largely in an exploratory phase. Radiation oncologists typically formulate individualized treatment plans based on tumor characteristics such as location, size, and morphology. Imaging modalities—particularly MRI and computed CT—enable accurate delineation of tumor boundaries and adjacent normal tissues, providing a critical foundation for precise applicator and needle placement. The number of interstitial needles required is determined by the location and volume of residual disease, while insertion depth is primarily guided by the craniocaudal extent (height) of the HR-CTV. Both transperineal template-guided and free-hand implantation approaches are clinically viable for delivering IC/IS brachytherapy. Moreover, 3D printing technology has been increasingly integrated into interstitial brachytherapy for cervical cancer, facilitating the fabrication of patient-specific needle templates that enhance procedural accuracy and reproducibility.¹² Notably, interstitial needle placement is technically demanding. In the absence of real-time image guidance, blind manual insertion or inadequate operator experience may result in tissue injury, vascular puncture, or significant bleeding. At present, most radiation oncology departments employ CT- or MRI-guided 3D brachytherapy for cervical cancer. CT imaging offers the advantage of rapid acquisition, making it well suited for intraoperative assessment and adjustment of uterine tandem position. Furthermore, CT-based planning enables robust optimization of dose distribution according to the prescribed treatment plan.¹³ MRI possesses inherent superiority over CT in soft-tissue contrast, allowing superior delineation of pelvic anatomy and tumor extent. However, its broader clinical implementation is hindered by longer scan times and logistical challenges related to compatibility with brachytherapy applicators and workflow. Nevertheless, MRI is frequently used during the preplanning phase to assess the feasibility of brachytherapy and identify potential procedural risks. Importantly, comparative studies have shown that dose distributions and rates of late OAR toxicities are comparable between MRI-based and CT-based brachytherapy approaches.¹⁴

The Groupe Européen de Curiethérapie–European Society for Radiotherapy and Oncology (GEC-ESTRO) defines V₁₅₀ and V₂₀₀ as the percentages of the HR-CTV receiving 150% and 200% of the prescribed dose, respectively. For OARs, D_0.1cc, D₁cc, D₂cc, D₅cc, and D₁₀cc denote the minimum doses delivered to the most highly irradiated 0.1, 1, 2, 5, and 10 cm³ of tissue volume, respectively.³ According to recommendations from the American Brachytherapy Society (ABS), when EBRT is combined with brachytherapy, the D₉₀—defined as the dose covering 90% of the HR-CTV—should exceed 80–90 Gy, expressed as the equivalent dose in 2 Gy fractions (EQD₂) using an α/β ratio of 10 Gy.¹⁵ Notably, D₂cc of the bladder—representing the minimum dose received by the most irradiated 2 cm³ of bladder tissue—is considered the dosimetric surrogate for the region of the bladder wall exposed to the highest radiation dose. This parameter is strongly associated with the incidence and severity of urinary morbidity.^16,17 Recent evidence suggests that ureteral stenosis is linked to bladder EQD₂ values exceeding 77 Gy.¹⁸ For the rectum, the maximum point dose correlates closely with the dose to the most irradiated 2 cm³ (D₂cc).¹⁹ A prior study demonstrated that both the frequency and severity of rectal toxicity are significantly reduced when rectal D₂cc is maintained at or below 65 Gy.²⁰

Notably, IS brachytherapy is associated with an increased risk of normal tissue injury and visceral perforation. Consequently, the incidence of late adverse events was slightly higher in patients treated with IMRT combined with HDR IS brachytherapy than in those receiving IMRT plus conventional IC brachytherapy. These late toxicities primarily included enterocutaneous fistula, urinary fistula, rectal stenosis, and small bowel obstruction. Although IS brachytherapy addresses the dosimetric limitations of standalone IC brachytherapy, the integration of IC and IS techniques in LACC treatment achieves mutual complementarity, thereby optimizing therapeutic outcomes. It must be emphasized, however, that interstitial implantation serves only as an adjunct to intracavitary brachytherapy—not as a replacement. Not all patients with LACC require interstitial implantation; the decision should be individualized based on specific tumor characteristics, including size, location, extent of infiltration, and anatomical constraints. Importantly, IS implantation demands rigorous quality assurance measures, including verification of radiation source placement accuracy and dose delivery precision. To minimize patient discomfort and ensure the accuracy and reproducibility of needle trajectory, position, and depth, implantation should be performed under image-guided localization whenever feasible, with appropriate anesthesia administered.

The present study is among the limited number of retrospective cohort studies evaluating differences in dose distribution between IC brachytherapy and combined IC/IS brachytherapy in patients with LACC. Nevertheless, several limitations must be acknowledged.First, the sample size was relatively small, and the study was conducted at a single institution. Moreover, subgroup analyses stratified by tumor location, tumor size, vaginal involvement, and parametrial extension were not performed due to insufficient statistical power. Second, the analysis focused exclusively on dosimetric comparisons of OAR exposure between the two techniques and did not include an assessment of subsequent clinical toxicity or adverse event incidence. Notably, investigating the correlation between the dosimetric profiles of these two brachytherapy approaches and the occurrence of treatment-related toxicities represents a critical direction for future research.

5. Conclusion

In summary, the clinical rationale for IS brachytherapy aligns with unmet needs in the management of LACC. With the widespread adoption of image-guided brachytherapy, the development of novel applicators, and advances in 3D printing technology, the future design of patient-specific templates and applicators is anticipated. These innovations are expected to enable truly individualized, precision brachytherapy, ultimately improving long-term survival outcomes and quality of life for patients with LACC. Nevertheless, standardized, large-scale, multicenter RCTs are still warranted to generate high-level evidence supporting the broader clinical implementation of combined IC/IS brachytherapy.

Supplemental Material

Supplemental Material - Dosimetric Comparison of Intracavitary Versus Combined Intracavitary-Interstitial Image-Guided Brachytherapy in Locally Advanced Cervical Cancer

Supplemental Material for Dosimetric Comparison of Intracavitary Versus Combined Intracavitary-Interstitial Image-Guided Brachytherapy in Locally Advanced Cervical Cancer by Xi Yang, Bo Zhao, Guiyong Yu, Zhuokai He, Meilian Liu, Rensheng Wang, Kai Hu in Dose-Response

Footnotes

Acknowledgements

We gratefully acknowledge Dr. Jianfeng Luo and Dr. Zuyue Bi for his statistical support and Dr. Xin Zhang for her valuable guidance on OAR delineation in the contouring atlas.

ORCID iD

Kai Hu

Author Contributions

Xi Yang: Conceptualization, Writing-original draft, Data curation; Guiyong Yu: Formal analysis; Bo Zhao and Zhuokai He: Methodology; Meilian Liu: Project administration; Rensheng Wang: Supervision; Kai Hu: Writing-review and editing, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the National Natural Science Foundation of China (No. 82060019); Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation (No. 2024GXNSFDA010042); and Guangxi Natural Science Foundation (No. 2024GXNSFBA010244).

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The data are available from the corresponding author for reasonable requests.*

Supplemental Material

Supplemental material for this article is available online.

References

Mourya

Choudhary

Shahi

, et al. A comparison between revised Manchester Point A and ICRU-89-recommended Point A definition absorbed-dose reporting using CT images in intracavitary brachytherapy for patients with cervical carcinoma. Brachytherapy. 2021;20(1):118-127. doi:10.1016/j.brachy.2020.07.009

Yoshida

Yamazaki

Takenaka

, et al. Preliminary results of MRI-assisted high-dose-rate interstitial brachytherapy for uterine cervical cancer. Brachytherapy. 2015;14(1):1-8. doi:10.1016/j.brachy.2014.07.006

Haie-Meder

Pötter

Van Limbergen

, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group☆ (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy and Oncology. 2005;74(3):235-245. doi:10.1016/j.radonc.2004.12.015

Pötter

Haie-Meder

Limbergen

, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy and Oncology. 2006;78(1):67-77. doi:10.1016/j.radonc.2005.11.014

Tanderup

Nesvacil

Kirchheiner

, et al. Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. Seminars in radiation oncology. 2020;30(4):311-327. doi:10.1016/j.semradonc.2020.05.008

Feder

Syed

Neblett

. Treatment of extensive carcinoma of the cervix with the “transperineal parametrial butterfly”: a prelimary report on the revival of Waterman’s approach. International journal of radiation oncology, biology, physics. 1978;4(7-8):735-742. doi:10.1016/0360-3016(78)90204-3

Kuipers

Hoekstra

CJM

van ’t Riet

, et al. HDR brachytherapy applied to cervical carcinoma with moderate lateral expansion: modified principles of treatment. Radiotherapy and Oncology. 2001;58(1):25-30. doi:10.1016/S0167-8140(00)00320-0

Georg

Kirisits

Hillbrand

Dimopoulos

Pötter

. Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. International journal of radiation oncology, biology, physics. 2008;71(4):1272-1278. doi:10.1016/j.ijrobp.2008.03.032

Fokdal

Sturdza

Mazeron

, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiotherapy and Oncology. 2016;120(3):434-440. doi:10.1016/j.radonc.2016.03.020

10.

Nomden

de Leeuw

AAC

Moerland

Roesink

Tersteeg

RJHA

Jürgenliemk-Schulz

. Clinical Use of the Utrecht Applicator for Combined Intracavitary/Interstitial Brachytherapy Treatment in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics. 2012;82(4):1424-1430. doi:10.1016/j.ijrobp.2011.04.044

11.

Sharma

Rath

Thulkar

Kumar

Subramani

Julka

. High-dose rate interstitial brachytherapy using two weekly sessions of 10 Gy each for patients with locally advanced cervical carcinoma. Brachytherapy. 2011;10(3):242-248. doi:10.1016/j.brachy.2010.09.001

12.

Lindegaard

Madsen

Traberg

, et al. Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer. Radiotherapy and Oncology. 2016;118(1):173-175. doi:10.1016/j.radonc.2015.12.012

13.

Sewchand

Prempree

Patanaphan

Whitley

Heidtman

Scott

. Value of multi-planar CT images in interactive dosimetry planning of intracavitary therapy. International journal of radiation oncology, biology, physics. 1982;8(2):295-301. doi:10.1016/0360-3016(82)90531-4

14.

Choong

Bownes

Musunuru

, et al. Hybrid (CT/MRI based) vs. MRI only based image-guided brachytherapy in cervical cancer: Dosimetry comparisons and clinical outcome. Brachytherapy. 2016;15(1):40-48. doi:10.1016/j.brachy.2015.09.002

15.

Viswanathan

Beriwal

De Los Santos

, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012;11(1):47-52. doi:10.1016/j.brachy.2011.07.002

16.

Viswanathan

Yorke

Marks

Eifel

Shipley

. Radiation Dose–Volume Effects of the Urinary Bladder. International Journal of Radiation Oncology*Biology*Physics. 2010;76(3, Supplement):S116-S122. doi:10.1016/j.ijrobp.2009.02.090

17.

Georg

Pötter

Georg

, et al. Dose Effect Relationship for Late Side Effects of the Rectum and Urinary Bladder in Magnetic Resonance Image-Guided Adaptive Cervix Cancer Brachytherapy. International Journal of Radiation Oncology*Biology*Physics. 2012;82(2):653-657. doi:10.1016/j.ijrobp.2010.12.029

18.

Sarwar

Eminowicz

. Radiotherapy induced ureteric stenosis in locally advanced cervical cancer: A review of current evidence. Brachytherapy. 2024;23(4):387-396. doi:10.1016/j.brachy.2024.03.002

19.

Hashim

Jamalludin

Ung

Malik

Phua

. CT based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses to the rectum and bladder. Asian Pacific journal of cancer prevention: APJCP. 2014;15(13):5259-5264. doi:10.7314/apjcp.2014.15.13.5259

20.

Mazeron

Fokdal

Kirchheiner

, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2016;120(3):412-419. doi:10.1016/j.radonc.2016.06.006

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB